2026. 05. 14

Meet us at ASCO 2026

Hello, this is GCCL. GCCL will be participating in ASCO 2026 (American Society of Clinical Oncology), the world’s largest oncology conference, held at McCormick Place in Chicago, USA, from May 29 to June 2. At ASCO 2026, GCCL will join the KoNECT Korea Pavilion (#12019)to connect with global pharmaceutical companies, biotech firms, CROs, and research institutions,expanding opportunities for collaboration in drug development.ASCO is a premier global event attended by over 40,000 oncology professionals worldwide,where the latest cancer treatment strategies, clinical data, and partnership opportunities are shared and discussed.Through ASCO 2026, GCCL aims to expand its global customer network and further strengthen its position as aleading clinical trial sample analysis CRO partner in the Asia-Pacific region. 📢🌐 Why Visit GCCL at ASCO?✅ Global quality system backed by CAP accreditation and GCLP compliance✅ Advanced laboratory operations powered by ddPCR, LIMS, and cutting-edge technologies✅ Extensive oncology-focused analytical expertise and global project experienceGCCL Booth Information at ASCO 2026📍 Booth: South Building Hall A, #12019 (KoNECT Pavilion)📅 Exhibition Dates: May 29 – June 2, 2026✉️ Meeting Inquiry: GCCL@gccorp.comGCCL supports global drug development partners with accurate and reliablebioanalytical and central lab services tailored for oncology clinical trials.At ASCO 2026, we look forward to introducing GCCL’s oncology-focused analytical capabilitiesand global collaboration experience.We look forward to meeting new partners shaping the future of cancer treatment at ASCO 2026.

2026. 05. 11

GCCL Supported the Journey of Korea’s First Approved CAR-T Therapy, “RIMQARTO®”

Hello, GCCL.A meaningful milestone has recently been achieved in Korea’s CAR-T therapy development landscape!QureCell’s CAR-T therapy “RIMQARTO®” (anbalcabtagene autoleucel) has officially received marketing authorization from the Ministry of Food and Drug Safety (MFDS),becoming the first domestically developed CAR-T therapy in Korea to enter commercialization. During the approval process, GCCL participated in the pivotal clinical trial “CRC01-01”,providing integrated Bioanalytical and Central Lab Services to support the clinical development program.RIMQARTO® is an orphan drug approved for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)and primary mediastinal B-cell lymphoma (PMBCL) after two or more lines of systemic therapy.This approval represents more than just a product authorization.💊 Commercialization of a domestically developed CAR-T therapy💊 Demonstration of Korea’s advanced biopharmaceutical development capabilities💊 Establishment of domestic manufacturing and supply infrastructure💊 Improved treatment accessibility for patients with refractory hematologic malignanciesIn a field that has long relied heavily on imported CAR-T therapies,the successful approval of a domestically developed treatment marks an important turning pointfor Korea’s biopharmaceutical industry.•·················•·················•GCCL supported the entire clinical analysis workflow for this study,from method development to project management. ✔ Method Development & Validation ✔ Bioanalytical Services ✔ Central Lab Operations ✔ Sample Collection, Transportation & Storage Management  ✔ Project Operations & Data Management  CAR-T clinical trials require significantly more complex analytical environments than conventional oncology studies.Comprehensive evaluation of immune responses, pharmacodynamic (PD) markers,genetic persistence, and safety-related biomarkers is essential,requiring high analytical sensitivity, reproducibility and sophisticated sample management systems.•·················•·················•GCCL supported these complex analytical requirements throughdiverse analytical platforms and extensive immunoassay expertise,while also ensuring stable and reliable data quality managementacross multi-center clinical trial environments in Korea.Building upon its previous experience supporting pivotal clinical trials for vaccine development,GCCL is proud to have contributed to another important milestonein the field of advanced biopharmaceuticals through this CAR-T therapy clinical program.   View GCCL’s Clinical Analysis Support for the Anthrax Vaccine “Barythrax”    GCCL continues to provide analytical support for follow-up clinical studies of the same therapy, further expanding its experience in CAR-T and Cell & Gene Therapy programs. Moving forward, GCCL will continue supporting the development of innovative therapeutics,including Cell & Gene Therapies, oncology drugs, and biopharmaceuticals,through its global-level analytical infrastructure and quality management systems.

2026. 04. 23

Meet us at BIO KOREA 2026

Hello, this is GCCL.GCCL will be participating in BIO KOREA 2026, which will be held at COEX, Seoul, from April 28 to 30, 2026, through business partnering meetings. Celebrating its 21st edition this year, BIO KOREA provides global collaboration opportunities through a wide range of programs. Among them, the Business Partnering program is designed to help participants identify the most suitable partners through an online scheduling system and maximize business outcomes.At this year’s event, GCCL plans to focus on partnering meetings to engage in more in-depth discussionswith global pharmaceutical companies, biotech firms, CROs, and other industry stakeholders. 📢 GCCL Key Highlights✔ One-Stop Lab CRO Solutions based on Central Lab & Bioanalytical Lab services✔ Analytical capabilities across key therapeutic areas, including oncology, CNS, and infectious diseases ✔ PK/PD, ADA, and biomarker analysis services ✔ Global clinical trial support strategies and partnership models 📅 DateApril 28 - 30, 2026📍 LocationCoex, Seoul, KoreaAs a leading Lab CRO supporting global clinical trials, GCCL provides integrated analytical solutions across the entire clinical trial lifecycle based on its Central Lab services and Bioanalytical Lab capabilities.In particular, GCCL has supported domestic and international clients in clinical development through a broad range of analytical services, including biomarker analysis, immune monitoring, PK, ADA, and NAb analysis.Through a flexible collaboration framework tailored to each project’s objectives and development stage, GCCL continues to expand its global partnerships.At the upcoming BIO KOREA, we invite you to discover GCCL’s specialized analytical expertise and extensive global project experience, and to explore the best collaboration strategies for the success of your clinical trials.

2026. 04. 08

GCCL at World Vaccine Congress 2026 in Washington D.C.

Hello, this is GCCL.GCCL participated in the World Vaccine Congress Washington 2026,held in Washington, D.C. from March 30 to April 2.World Vaccine Congress is one of the leading global events where companies, research institutions, and experts in the vaccine industry come togetherto share the latest trends in R&D, technologies, clinical strategies, and partnership opportunities.At this year’s event, GCCL had the opportunity to engage with many industry professionalsthrough a variety of activities, including exhibiting at our booth, presenting a research poster, holding global partnering meetings, and attending program sessions.Today, we would like to share a glimpse of our experience on site.1️⃣ GCCL Exhibition BoothThroughout the event, GCCL operated an independent booth andintroduced our specialized analytical services for vaccine and therapeutic developmentto global pharmaceutical and biotech companies, research institutions, and vaccine development stakeholders.At the booth, we highlighted GCCL’s capabilities in vaccine and infectious disease analysis, includingneutralizing antibody analysis, immunogenicity testing, biomarker analysis, Central Lab services, and bioanalytical services to support vaccine development. In particular, GCCL introduced its strengths as a reliable partner for global clinical trials, built on aGCLP-based clinical sample testing system and extensive experience in performing a wide range of analyses required throughout the vaccine development process.Another meaningful outcome of the event was the opportunityto communicate directly with a wide range of industry professionals andgain a more concrete understanding of current market interests and actual analytical needs.2️⃣ Research Poster Presentation on the FRNT AssayAt this year’s event, GCCL also presented a research poster developed by Research Team 2:Development and Optimization of an Automated Focus Reduction Neutralization Test (FRNT) Assay for Evaluating RSV Neutralizing Antibody TitersFRNT is an important analytical method used to assess viral neutralizing activityduring vaccine and antibody therapeutic development,where accuracy and reproducibility are especially critical.Through this poster, GCCL introduced the development and optimization process of anautomated FRNT assay for RSV, demonstrating the potentialfor more efficient and consistent analytical performance.This presentation reflected GCCL’s ongoing efforts to strengthen its capabilities beyond routine testing,particularly in assay development and optimization for vaccine development.On site, the poster also led to technical discussions with attendees and drew interest inGCCL’s expertise in vaccine-related analysis. 3️⃣ Global Partnering and Business MeetingsAnother important part of WVC was the wide range of partnering meetings held throughout the event.During the congress, GCCL met with representatives from various companies and institutions to discussdevelopment directions in the vaccine and infectious disease fields, analytical needs, and potential areas for future collaboration.Because each company is at a different stage of development and requires highly specific analytical support,even short meetings provided valuable insights.These partnering meetings gave GCCL a meaningful opportunityto better understand the needs of the global market and further considerhow we can support clients in more practical and tailored ways.In particular, meeting stakeholders from North America, Europe, and Asiahelped GCCL expand business opportunities and identifybroader points of connection within the global vaccine development ecosystem.4️⃣ MOU Signing with VisMederiDuring the event, GCCL also signed an MOU with VisMederi, an Italy-based analytical institution specializing in vaccines and infectious diseases.VisMederi has strong expertise in the vaccine and infectious disease field, and this agreement marked ameaningful starting point for expanding global collaboration based on the strengths of both organizations.Through this MOU, GCCL will contribute its experience and operational capabilities in the Asia region, while VisMederi brings its expertise and network in Europe, creating opportunities for mutual synergy.At a time when global collaboration is becoming increasingly important in the vaccine and infectious field,this agreement is particularly meaningful as it establishes a foundationfor closer cooperation between the two organizations.The signing ceremony held during the event was also a memorable moment for GCCL, raising expectations forthe possibilities the two organizations may create together going forward.📌 For more details about the partnership,please visit the official press release.5️⃣ Attending Program SessionsIn addition to exhibiting and holding meetings, GCCL also attended various program sessions to explorethe latest trends in the global vaccine industry.At the event, a wide range of topics were covered, including next-generation vaccine platforms,infectious disease response strategies, clinical development and regulatory issues, immune response evaluation, pandemic preparedness, and global collaboration.It was a valuable opportunity to see firsthandwhich technologies and strategies are drawing attention in today’s rapidly evolving vaccine landscape.Following these discussions and industry movements on site was also highly meaningful for GCCL,as it helps us better understand customer needs andfurther advance our service direction and technical capabilities.Overall, participating in World Vaccine Congress Washington 2026 was a valuable experience for GCCL.It allowed us to engage directly with stakeholders across the global vaccine industry,better understand on-the-ground needs, andintroduce both our analytical expertise and collaboration potential.GCCL will continue to provide reliable analytical services across a wide range of global clinical trial areas, including vaccines and infectious diseases,and remain a trusted partner supporting our clients’ successful development programs.We will continue to serve as a trusted clinical trial partner for our clients.To learn more about GCCL, please click the banner below.

2026. 03. 30

2026 1Q Newsletter

2026. 03. 18

GCCL Hosts Clinical Sample Analysis (GCLP) Training in Collaboration with KSQA

GCCL Hosts Clinical Sample Analysis (GCLP) Training in Collaboration with KSQAStrengthening quality capabilities to deliver more reliable and consistent servicesGCCL hosted the 2026 Clinical Sample Analysis (GCLP) Training on March 17, 2026, at Room R300, 3rd Floor, GC R&D Center, in collaboration with the Korean Society of Quality Assurance (KSQA). The program was organized for participants across the GC Group as part of GCCL’s ongoing efforts to reinforce quality standards and enhance operational excellence in clinical sample analysis.As clinical trials become increasingly complex and expectations surrounding regulatory compliance, data reliability, and quality management continue to rise, organizations involved in clinical sample analysis are expected to maintain not only technical expertise but also a strong and consistent quality mindset. Against this backdrop, GCCL planned this training to provide a practical and meaningful learning opportunity for GC Group affiliates, with the goal of deepening understanding of GCLP principles and strengthening the overall quality of related operations.The training program covered a range of key topics relevant to today’s clinical sample analysis environment. The session opened with welcoming remarks from Kwan Goo Cho, CEO of GCCL, followed by a presentation on GCLP preparation documents and record retention requirements. This session highlighted the importance of establishing and maintaining proper documentation practices in accordance with clinical trial sample analysis standards, emphasizing that robust document control is a fundamental part of quality-based laboratory operations.The program also included a session on the latest GCLP trends, from chain of custody to data integrity, addressing areas that have become increasingly important in clinical sample analysis. As traceability, accountability, and reliable data handling continue to receive greater attention across the industry, the session offered practical insight into how these principles should be applied throughout the analytical process. In particular, it reinforced the idea that consistent quality is built not only on analytical performance itself, but also on the processes and systems that support every stage of sample handling and data management.Another session focused on changes in the clinical trial environment and understanding sponsor expectations. As sponsor requirements become more sophisticated and project needs more specialized, laboratory service providers are increasingly expected to demonstrate not only technical capabilities, but also a clear understanding of client expectations, regulatory considerations, and study-specific quality demands. This part of the program provided participants with a broader perspective on how the clinical landscape is evolving and what that means for organizations supporting clinical development.The final session addressed inspection readiness and response, offering practical guidance on how to prepare for and respond to inspections effectively. This topic was particularly meaningful in helping participants better understand the operational discipline and readiness required to support high-quality clinical sample analysis under real-world conditions.More than a one-time educational event, this training served as a valuable opportunity to share knowledge, align on quality expectations, and reinforce a common understanding of best practices across the GC Group. By covering both foundational principles and current industry considerations, the program helped participants connect day-to-day laboratory and operational practices with the broader objective of maintaining high standards in clinical sample analysis.For GCCL, initiatives such as this training reflect a broader commitment to continuous improvement. Delivering reliable and consistent services requires more than technical infrastructure alone; it also depends on strong documentation practices, regulatory awareness, inspection readiness, and a shared quality culture across the organization. Through this program, GCCL sought to further strengthen those capabilities and contribute to a more robust quality foundation for future operations.GCCL believes that ongoing education and collaboration are essential to elevating overall service quality. By working together with organizations such as KSQA and engaging participants across the GC Group, GCCL aims to foster a culture of quality that supports not only internal capability building, but also better outcomes for partners and clients.GCCL extends its sincere appreciation to KSQA, all speakers, and all participants who contributed to making this training a meaningful and productive session. Going forward, GCCL will continue to pursue opportunities for education, collaboration, and quality enhancement in order to provide dependable, high-quality clinical sample analysis services in a rapidly evolving clinical development environment.Please feel free to contact us!📩 Email:GCCL@gccorp.comGCCL is committed to being your most reliable clinical trial partner, delivering value and trust across every project.Click the banner below to learn more about us!

2026. 03. 12

Meet us at World Vaccine Congress 2026 in Washington D.C.

GCCL will be attending World Vaccine Congress 2026, taking place from March 30 to April 2, 2026, in Washington, D.C., USA,where we will welcome global vaccine and biopharma partners at Booth 252.World Vaccine Congress is one of the industry’s leading global events, bringing together vaccine developers, pharmaceutical and biotech companies, researchers, and solution providers to discuss the latest trends and innovations shaping vaccine and therapeutic development. GCCL is pleased to join this year’s event and connect with partners from across the industry.During the congress, GCCL will showcase its integrated central lab, bioanalytical, and assay development capabilities that support vaccine and therapeutic development throughout the clinical trial process. Our team will be available to discuss how GCCL helps clients generate reliable data and advance their development programs through tailored laboratory services and collaborative scientific support.In addition to exhibiting at Booth 252, GCCL will also present its latest research on the development and optimization of an automated Focus Reduction Neutralization Test (FRNT) assay for evaluating RSV neutralizing antibody titers. This research highlights GCCL’s ongoing efforts to strengthen analytical capabilities that can support vaccine and therapeutic developers in immunogenicity assessment and related studies.For attendees planning to join WVC 2026, we warmly invite you to schedule a meeting with our team in advance. We look forward to exploring potential collaboration opportunities and sharing how GCCL can support your clinical development needs.As Washington, D.C. welcomes visitors during cherry blossom season, we hope to meet many of our global partners there and have meaningful conversations throughout the event.Event InformationEvent: World Vaccine Congress 2026Date: March 30–April 2, 2026Location: Washington, D.C., USABooth: 252Exhibitor Profile & Meeting Requesthttps://app.terrapinn.com/event/world-vaccine-congress-washington-2026/exhibitor/RXhoaWJpdG9yXzI0MTczNzM=Please feel free to contact us!📩 Email:GCCL@gccorp.comGCCL is committed to being your most reliable clinical trial partner, delivering value and trust across every project.Click the banner below to learn more about us!

2025. 12. 29

Happy New Year from GCCL

새해를 맞이하며,GCCL은 고객, 파트너 여러분께 진심으로 감사드립니다.그리고 전 세계 협력자 여러분께서 지속적인 신뢰와 파트너십을 보여주신 데 대해 진심으로 감사드립니다.지난 한 해 동안 우리는 글로벌 바이오테크 및 제약 회사들과 협력해 왔습니다.신뢰할 수 있는 생체 분석 및 중앙 실험실 솔루션을 통해 임상 시험을 지원합니다.이러한 공동의 노력과 연결은 우리의 발전을 위한 토대가 되었습니다.저희는 앞으로 다가올 2026년에도 함께 성장해 나가기를 기대합니다.건강하고 성공적이며 영감 넘치는 새해 되세요! 🤝

2025. 12. 24

2025 4Q Newsletter

2025. 12. 15

Meet us at Biotech Showcase 2026 during JPM week

Hello from GCCL.GCCL, a leading central lab based in APAC, is participating at Biotech Showcase 2026 from January 12–14 in San Fransico, USA!GCCL is pleased to announce its participation in Biotech Showcase 2026, taking place during JPM Week in San Francisco, one of the most influential global gatherings for the biotechnology and pharmaceutical industries.Company Presentation at Biotech Showcase 2026As part of the official conference program, GCCL’s CEO will deliver a company presentation highlighting GCCL’s role as a global clinical sample analysis partner. The presentation will focus on GCCL’s end-to-end central laboratory services and advanced bioanalytical solutions designed to support complex global clinical trials across multiple regions.Company Presentation DetailsDate & Time: January 13, 2026 | 10:00 AMLocation: Franciscan C, San FranciscoDuring the presentation, GCCL will introduce its integrated service framework, including central lab operations, bioanalytical testing, and global project coordination, emphasizing how these capabilities enable scientific rigor, operational consistency, and efficiency for international clinical development programs.Partnering Meetings During JPM WeekIn addition to the company presentation, GCCL will actively participate in one-on-one partnering meetings throughout Biotech Showcase 2026. The GCCL team will be available to meet with biotech and pharmaceutical companies seeking a reliable central lab and bioanalytical partner for global clinical trials.Partnering Dates & LocationDates: January 12–14, 2026Venue: Hilton San Francisco – Union SquareStrengthening Global Clinical Trial PartnershipsGCCL’s participation in Biotech Showcase 2026 reflects its continued commitment to expanding global partnerships and supporting sponsors with high-quality clinical sample analysis solutions.By combining central lab services with specialized bioanalytical expertise, GCCL serves as a strategic partner for sponsors navigating increasingly complex global clinical trial environments.GCCL looks forward to engaging in meaningful discussions, sharing insights, and building new collaborations with global biotech and pharma partners during JPM Week 2026.For partnering inquiries, please visit GCCL’s official partnering profile on the Biotech Showcase platform.https://partneringone.informaconnect.com/event/820/profile/user/760/company/563Please feel free to contact us!📩 Email:GCCL@gccorp.comGCCL is committed to being your most reliable clinical trial partner, delivering value and trust across every project.Click the banner below to learn more about us!